Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital

Roth Capital upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH - Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports.

A number of other research firms also recently issued reports on RVPH. EF Hutton Acquisition Co. I raised Reviva Pharmaceuticals to a "strong-buy" rating in a research note on Monday, September 23rd. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research report on Friday. They issued a "buy" rating and a $7.00 price target on the stock. Finally, Maxim Group upgraded shares of Reviva Pharmaceuticals from a "hold" rating to a "buy" rating and set a $7.00 price objective for the company in a research report on Friday. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $11.25.

Reviva Pharmaceuticals Trading Up 0.5 %

RVPH traded up $0.01 on Friday, hitting $1.88. 4,428,758 shares of the company's stock traded hands, compared to its average volume of 3,583,320. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83. The firm has a market cap of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12. The company's 50 day simple moving average is $1.56 and its 200-day simple moving average is $1.29.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) by 17.9% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 278,496 shares of the company's stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. 63.18% of the stock is currently owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.